Advertisement

NEW ORLEANS, May 21 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV™ (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), at a major psychiatric meeting.  The primary objective of this study was to evaluate the efficacy of INTUNIV, dosed either in the morning or evening compared with placebo, when co-administered with stimulant medications used to treat ADHD in children and adolescents ages 6 to 17 with ADHD and suboptimal response to stimulant alone.  The study met its primary end point, which was the change from baseline to end point in the ADHD Rating Scale-IV (ADHD RS-IV) total score.

"A considerable number of pediatric pat

'/>"/>

SOURCE

Advertisement
Advertisement